To Evaluate the Efficacy and Safety of HUC3-053 in Patients with Dry Eye Syndrome
Status:
RECRUITING
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blinded, non-inferiority study to evaluate the efficacy and safety of HUC3-053 in patients with dry eye syndrome.
After a 2-week run-in period, patients will be randomized equally to the HUC3-053 or Hyalein Mini Drops administered bilaterally five to six times a day for 12 weeks.